Foghorn Therapeutics (FHTX) Non-Current Deffered Revenue (2020 - 2026)

Foghorn Therapeutics' Non-Current Deffered Revenue history runs 7 years deep, the most recent figure standing at $193.6 million for Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 12.97% year-over-year to $193.6 million in Q1 2026; TTM through Mar 2026 was $193.6 million, a 12.97% decrease from a year earlier, with the FY2025 full-year figure at $206.0 million, down 12.15% from the prior year.
• Non-Current Deffered Revenue declined to $193.6 million in Q1 2026 per FHTX's latest filing, from $206.0 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $317.1 million in Q1 2022 and bottomed at $193.1 million in Q3 2025.
• The 5-year median for Non-Current Deffered Revenue is $266.1 million (2024), against an average of $259.5 million.
• Across the five-year window, Non-Current Deffered Revenue surged 16324.84% in 2022 and decreased 22.62% in 2025, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $304.0 million in 2022, then declined by 11.8% to $268.1 million in 2023, then fell by 12.55% to $234.5 million in 2024, then retreated by 12.15% to $206.0 million in 2025, then fell by 6.01% to $193.6 million in 2026.
• Per Business Quant, the three latest FHTX Non-Current Deffered Revenue figures stand at $193.6 million (Q1 2026), $206.0 million (Q4 2025), and $193.1 million (Q3 2025).